Merck KGaA has expanded its collaboration with Quris-AI, a company specialising in artificial intelligence (AI) solutions.
The initial partnership aimed to compare Quris' BioAI safety prediction platform with traditional methods for assessing drug safety. This platform combines miniaturised human tissues, nanosensing, and machine learning to predict the safety of potential drug candidates.
After 19 months of collaboration, Merck has decided to expand the agreement. The expanded deal will allow Merck to use BioAI to identify potential liver toxicity risks in a selection of drug candidates. Additionally, it grants Merck an option for exclusive technology licensing in a specific disease domain for up to five years.
The goal of this collaboration is to develop an AI-enabled investigational new drug (IND) process that reduces the need for animal testing, ultimately improving the efficiency of research and development (R&D) while reducing time and costs.
Click here to read the original news story.